Nalin D - Search Results

1

Control of hepatitis A through routine vaccination of children.

Averhoff F, Shapiro CN, Bell BP, Hyams I, Burd L, Deladisma A, Simard EP, Nalin D, Kuter B, Ward C, Lundberg M, Smith N, Margolis HS. Averhoff F, et al. Among authors: nalin d. JAMA. 2001 Dec 19;286(23):2968-73. doi: 10.1001/jama.286.23.2968. JAMA. 2001. PMID: 11743837

2

Hepatitis infections in the day-care setting.

Hurwitz ES, Deseda CC, Shapiro CN, Nalin DR, Freitg-Koontz MJ, Hayashi J. Hurwitz ES, et al. Among authors: nalin dr. Pediatrics. 1994 Dec;94(6 Pt 2):1023-4. Pediatrics. 1994. PMID: 7971045 No abstract available.

3

Six years' follow-up after hepatitis A vaccination.

Werzberger A, Kuter B, Nalin D. Werzberger A, et al. Among authors: nalin d. N Engl J Med. 1998 Apr 16;338(16):1160. doi: 10.1056/nejm199804163381615. N Engl J Med. 1998. PMID: 9547152 No abstract available.

4

Duration of protection from clinical hepatitis A disease after vaccination with VAQTA.

Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, Kuter BJ, Nalin DR. Wiens BL, et al. Among authors: nalin dr. J Med Virol. 1996 Jul;49(3):235-41. doi: 10.1002/(SICI)1096-9071(199607)49:3<235::AID-JMV13>3.0.CO;2-B. J Med Virol. 1996. PMID: 8818971

5

Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA.

Werzberger A, Mensch B, Nalin DR, Kuter BJ. Werzberger A, et al. Vaccine. 2002 Mar 15;20(13-14):1699-701. doi: 10.1016/s0264-410x(02)00042-7. Vaccine. 2002. PMID: 11906754 Clinical Trial.

6

Inactivated hepatitis A vaccine in childhood: implications for disease control.

Nalin D, Brown L, Kuter B, Patterson C, McGuire B, Werzberger A, Santosham M, Block S, Reisinger K, Watson B, et al. Nalin D, et al. Vaccine. 1993;11 Suppl 1:S15-7. doi: 10.1016/0264-410x(93)90152-n. Vaccine. 1993. PMID: 8383388 Clinical Trial.

7

Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin.

Shouval D, Ashur Y, Adler R, Lewis JA, Miller W, Kuter B, Brown L, Nalin DR. Shouval D, et al. Among authors: nalin dr. J Hepatol. 1993;18 Suppl 2:S32-7. doi: 10.1016/s0168-8278(05)80375-7. J Hepatol. 1993. PMID: 8182270 Clinical Trial.

8

Sensitive assays for hepatitis A antibodies.

Miller WJ, Clark W, Hurni W, Kuter B, Schofield T, Nalin D. Miller WJ, et al. Among authors: nalin d. J Med Virol. 1993 Nov;41(3):201-4. doi: 10.1002/jmv.1890410306. J Med Virol. 1993. PMID: 8263501

9

Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview.

Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, Shouval D, Ellerbeck E, Block SL, Bishop R, et al. Nalin DR, et al. J Hepatol. 1993;18 Suppl 2:S51-5. doi: 10.1016/s0168-8278(05)80379-4. J Hepatol. 1993. PMID: 8182275 Review.

10

Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers.

Midthun K, Ellerbeck E, Gershman K, Calandra G, Krah D, McCaughtry M, Nalin D, Provost P. Midthun K, et al. Among authors: nalin d. J Infect Dis. 1991 Apr;163(4):735-9. doi: 10.1093/infdis/163.4.735. J Infect Dis. 1991. PMID: 1849160 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

159 results

Search Page